{"name":"Anavex Life Sciences Corp.","slug":"anavex-life-sciences-corp","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":37592000,"netIncome":-46377000,"cash":103815000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"ANAVEX2-73","genericName":"ANAVEX2-73","slug":"anavex2-73","indication":"Alzheimer's disease","status":"phase_3"},{"name":"ANAVEX2-73 Intravenous","genericName":"ANAVEX2-73 Intravenous","slug":"anavex2-73-intravenous","indication":"Alzheimer's disease","status":"phase_2"},{"name":"ANAVEX2-73 oral liquid","genericName":"ANAVEX2-73 oral liquid","slug":"anavex2-73-oral-liquid","indication":"Alzheimer's disease","status":"phase_2"},{"name":"ANAVEX3-71 oral capsules","genericName":"ANAVEX3-71 oral capsules","slug":"anavex3-71-oral-capsules","indication":"Alzheimer's disease","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ANAVEX3-71","genericName":"ANAVEX3-71","slug":"anavex3-71","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ANAVEX2-73","genericName":"ANAVEX2-73","slug":"anavex2-73","phase":"phase_3","mechanism":"ANAVEX2-73 is a sigma-1 receptor agonist that activates neuroprotective pathways to treat neurodegenerative diseases.","indications":["Alzheimer's disease","Parkinson's disease dementia"],"catalyst":""},{"name":"ANAVEX2-73 Intravenous","genericName":"ANAVEX2-73 Intravenous","slug":"anavex2-73-intravenous","phase":"phase_2","mechanism":"ANAVEX2-73 is a small molecule that modulates sigma-1 receptors and muscarinic acetylcholine receptors, which may have neuroprotective effects.","indications":["Alzheimer's disease","Parkinson's disease"],"catalyst":""},{"name":"ANAVEX2-73 oral liquid","genericName":"ANAVEX2-73 oral liquid","slug":"anavex2-73-oral-liquid","phase":"phase_2","mechanism":"ANAVEX2-73 is an oral liquid formulation of a sigma-1 receptor agonist.","indications":["Alzheimer's disease","Parkinson's disease"],"catalyst":""},{"name":"ANAVEX3-71","genericName":"ANAVEX3-71","slug":"anavex3-71","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ANAVEX3-71 oral capsules","genericName":"ANAVEX3-71 oral capsules","slug":"anavex3-71-oral-capsules","phase":"phase_2","mechanism":"ANAVEX3-71 is a sigma-1 receptor agonist that modulates neuroprotective and neuroinflammatory pathways in the central nervous system.","indications":["Alzheimer's disease","Parkinson's disease"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOYko3NFdTdnpQZVI5MGVhVkxBbC16eWhPNGNraUgwcnhlNERoMXlfbzdrSEtJMkZ6MUUzd09fQ3Jiai00NkFRQ3EyWkVXU0I1VjZxZEJUUlNMTUJ1VEQ1NTZ1bG9OOGhZZWJLNHFGa1czaGZYb2gzZHZkRzNrOERCV3NneVE0UjZnZ3VnTU9jMnFDaldJcldHcE93WUcyM25pMGNMUk1rV3VKb0k?oc=5","date":"2026-04-07","type":"pipeline","source":"BioCentury","summary":"Precision mTOR targeting aims to widen the window in TSC epilepsy - BioCentury","headline":"Precision mTOR targeting aims to widen the window in TSC epilepsy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPNmt2dTlYQ1VoVW8wT052NUh1NEo4d29haEMwd2NTcFBuemlSZ3lnYkVwNDI2RmlOQi1FMDVkZnlKNGpyb3dYb29jUE01R21BUWl3OVc1ejgxQ2R0TG12MTdIMFVTS1BNZTF1bXVyT1otd2hrcTNNN2lPYndjZGFkRTdBZGwzNlpGT0RHaW9PY29sdEFQdlBaUzZHRmtpNFpxRkYwXzFzdw?oc=5","date":"2026-03-27","type":"regulatory","source":"BioWorld News","summary":"EMA to withdraw approval for Siga’s tecovirimat in treating mpox - BioWorld News","headline":"EMA to withdraw approval for Siga’s tecovirimat in treating mpox","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxOYnJ4Uk9NZUszOVBXRGZ5T01lUzBvQzBQNC1IY3NVRExnRU16Xzl3LTFnTnpLN3RsTTdTVkM4MUxoM2ZBangwMmRzZXJxc3dndEN1M25kRW9HSHN2eHJYcl9RVV91a2tsWm1PYmRLTDk0a01oT05xRF94SnZMbVZEOElMaw?oc=5","date":"2026-03-25","type":"pipeline","source":"pharmaphorum","summary":"Anavex sinks after pulling Alzheimer's filing in EU - pharmaphorum","headline":"Anavex sinks after pulling Alzheimer's filing in EU","sentiment":"neutral"},{"date":"2026-03-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNUTlBMXJCN0MzODBoT2JGaWdKaVZHSEh0NEY5RS0tXzY1MmlBeGszc2k1UkFDV25LRTlQNW56aVFMeWdMcGNkMGlIYTZXQlFGWURvYjhaRUYtUktSbkNJUy1BSGI5SjZVMkZHeEJmOFRqOThxazJFaUtMUldGWUM4TVdleDV3QnBjTWk3SGI5OU5qaWVRVUE?oc=5","date":"2026-02-12","type":"pipeline","source":"PharmTech.com","summary":"European Biotechs Impacting Treatment of Alzheimer’s Disease - PharmTech.com","headline":"European Biotechs Impacting Treatment of Alzheimer’s Disease","sentiment":"neutral"},{"date":"2026-02-09","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2026-02-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxPcGRqQXpkVk1IaGlkS3A1eHo2TUVKakFJVWRwNEFnODlwQUd4QXJIQ1FxOEVudTFyUktjbkFtR2JNaVhacDZXRUw5b2Y1V3RMb1ZRTHNpblI2TWk3NWlmWE80cnc1aHppdXZQMlpBM0JUaWJieWtkanMzX3dzN1VnMVRyZnpIdFFpRy0zMkwzX1hvQXdXNUxXdE9IT3Z0RlAzRVU3SmdROE1KUGhPc3Nhay1Vc09idjIxcExxZndEc3RNZ1o2TGhBTm5PNTQ4YTA4VVhmRFl3LUt3MEVvZkFOd1NGLVNfODgtYU93RU13cWJfUQ?oc=5","date":"2025-12-12","type":"regulatory","source":"TechStock²","summary":"Anavex Life Sciences (AVXL) Stock Drops After EMA Recommends Refusal of Blarcamesine: Latest News, Analyst Forecasts, and What’s Next (Dec. 12, 2025) - TechStock²","headline":"Anavex Life Sciences (AVXL) Stock Drops After EMA Recommends Refusal of Blarcamesine: Latest News, Analyst Forecasts, an","sentiment":"neutral"},{"date":"2025-11-25","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: FORM 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2025-11-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-11-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPMDBDWWotWTFTb1pvSC1mbk1wTnVJZUNJSnVfY2I5V0VTRUVrQm9UbEZUem9WaG01RGc4T2VoNHAxUy1SMGdyemFPaURIOHFud0hFNmJSaWpJcW5iWFpIR3doWGRXOC1ldE1GSkY0T2w0bDFPU1BZZ2U1UkUzOXlraUdBa3Y4N0xGMlE?oc=5","date":"2025-11-07","type":"earnings","source":"StocksToTrade","summary":"Recursion Pharmaceuticals Faces Steep Revenue Miss Amid Market Pressures - StocksToTrade","headline":"Recursion Pharmaceuticals Faces Steep Revenue Miss Amid Market Pressures","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxPeUx4N1VxLVVxc28zWUFqN2xxa0gwU2xfY2FldkpYcDBDNmFxR2V0azFwVXhGN0dNZFJTd3ZXVzU4cHYtbzZHUmNxVUhKandmdlhuOXM1UHRPbTV6VUs0NEt3WnlSYkZib2JaYTcwM1dOTmlSRzJId0E4bXF1M1FCcmJ6QzFQQ0VtZFVkWGN5aGM0X0FmY1RtQWEzZlNqWWtFQ0pmUHZvNU9SV3Q5LUdiekNaZmo0U2xZNkROM2lMQ05MM1REWkMtLUlYVDg3a29idE4zU3NPekFLRHJUeTZNRzhSSFkzQUhfV0VVbWRTcEtFclpHcUxVYXdXT2JINkhubFBNSzlJSldFMHEyLTliclQwTGpyVlNEWG5XRzdR?oc=5","date":"2025-08-12","type":"trial","source":"GlobeNewswire","summary":"Cannabinoid Clinical Trial Pipeline Gains Momentum: 50+ - GlobeNewswire","headline":"Cannabinoid Clinical Trial Pipeline Gains Momentum: 50+","sentiment":"neutral"},{"date":"2025-08-12","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_3":1,"phase_2":3,"phase_1":1},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":37592000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-46377000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":103815000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}